Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
REDWOOD CITY, Calif., May 01, 2018 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that the Company will report first quarter 2018 financial results and operational highlights on Tuesday, May 8th, 2018. OncoMed will not be conducting a conference call in conjunction with this earnings release.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Anti-TIGIT (OMP-313M32), navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), and rosmantuzumab (anti-RSPO3, OMP-131R10) are part of OncoMed's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. For further information about OncoMed Pharmaceuticals, please see www.oncomed.com.
Investor Relations Contact:
Matthew Beck
Solebury Trout
[email protected]
(646) 378-2933
